(153 days)
Not Found
No
The device description and performance studies indicate a simple immunochromatographic test, with no mention of AI or ML technologies.
No
This device is an immunoassay for the detection of drugs of abuse, used for screening purposes, not for treating any condition.
Yes
The "Intended Use / Indications for Use" section explicitly states, "For in vitro Diagnostic Use." Additionally, the device is described as an "Immunoassay for the qualitative detection of THC metabolite, opiates, cocaine metabolite, methamphetamine in urine to assist in screening of drugs of abuse," which is a diagnostic purpose.
No
The device description explicitly states it is an "immunochromatographic test," which is a physical test strip or kit, not a software-only device.
Yes, based on the provided text, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: Both "Intended Use / Indications for Use" sections clearly state: "For in vitro Diagnostic Use."
- Nature of the Test: The device performs an "Immunoassay for the qualitative detection of THC metabolite, opiates, cocaine metabolite, methamphetamine in urine." This is a laboratory test performed on a biological sample (urine) outside of the body to provide information about a person's health status (in this case, the presence of drugs of abuse). This is the definition of an in vitro diagnostic test.
- Intended Use: The intended use is to "assist in screening of drugs of abuse." This is a diagnostic purpose.
Therefore, the device described is definitively an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
Status Stik™ THC/OPI/COC/MET is designed for the qualitative detection of THC at the cutoff of 50 ng/mL 11-nor-Δ-THC-9-carboxylic acid, opiates at the cutoff of 2000 ng/mL morphine, cocaine at the cutoff of 300 ng/mL benzoylecgonine, and methamphetamine at the cutoff of 1000 ng/mL dmethamphetamine in human urine to assist in screening of drugs of abuse samples. For In vitro Diagnostic Use.
LifeSign® Home Drug Test is designed for the qualitative detection of THC at the cutoff of 50 ng/mL 11-nor-A2-THC-9-carboxylic acid, opiates at the cutoff of 2000 ng/mL morphine, cocaine at the cutoff of 300 ng/mL benzoylecgonine, and methamphetamine at the cutoff of 1000 ng/mL d-methamphetamine in human urine to assist in screening of drugs of abuse samples. For In vitro Diagnostic Use. This test is intended for use in the home to assist in preventing drug abuse.
Immunoassay for the qualitative detection of THC metabolite, opiates, cocaine metabolite, methamphetamine in urine to assist in screening of drugs of abuse. For in vitro Diagnostic Use.
Immunoassay for the qualitative detection of THC metabolite, opiates, cocaine metabolite, methamphetamine in urine to assist in screening of drugs of abuse samples at home or work places. For in vitro Diagnostic Use.
Product codes (comma separated list FDA assigned to the subject device)
MVO, DJC, LDJ, DIO, DJG
Device Description
Stik™ THC/OPI/COC/MET is simple one step immunochromatographic test for the rapid, qualitative, simultaneous detection of THC, opiates, cocaine, and methamphetamine.
LifeSign® Home Drug Test (THC/OPVCOC/MET) is simple one step immunochromatographic test for the rapid, qualitative, simultaneous detection of THC, opiates, cocaine, and methamphetamine.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Professional Use: X (Per 21 CFR 801.109)
Over The Counter Use: X
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The tests demonstrated 100 % correlation when more than 90 specimens for each drug were compared respectively.
In a consumer study, LifeSign® Home Drug Test (THC/OPI/COC/ MET) showed over 95% overall accuracy.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3870 Cannabinoid test system.
(a)
Identification. A cannabinoid test system is a device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marihuana, in serum, plasma, saliva, and urine. Cannabinoid compounds includedelta -9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use.(b)
Classification. Class II (special controls). A cannabinoid test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
MAY 2 3 2002
510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR Part 807.92.
The assigned 510(k) number is: _ K 014193
-
- Date of Summary: Dec.12, 2001
Princeton BioMeditech Corperation 2. Submitted by: 4242 U.S. Route 1, Monmouth Jct., NJ 08852 PHONE 732-274-1000 FAX 732-274-1010 Contact Person: Jemo Kang, Ph.D., Director
- Date of Summary: Dec.12, 2001
-
- Device Name
Trade Names: Stick: Status Stik™ THC/OPI/COC/MET, AccuSign®Stik THC/OPI/COC/MET, AccuStik™ DOA4 Card: AccuSign® DOA4, Status DSTM DOA4 Strip: AccuStrip™ DOA4 Common or Usual Name: Immunoassay for detection of THC, opiates, cocaine, and methamphetamine in urine Classification Name: Drugs of Abuse Analysis Systems, Toxicology (91DKE, 91DJG, 91DIO for Enzyme Immunoassay, 91LAG for HPLC)
- Device Name
-
Stik™ THC/OPI/COC/MET is simple one step Status 5. Device Description: immunochromatographic test for the rapid, qualitative, simultaneous detection of THC, opiates, cocaine, and methamphetamine.
-
- Intended Use: Status Stik™ THC/OPI/COC/MET is designed for the qualitative detection of THC at the cutoff of 50 ng/mL 11-nor-Δ -THC-9-carboxylic acid, opiates at the cutoff of 2000 ng/mL morphine, cocaine at the cutoff of 300 ng/mL benzoylecgonine, and methamphetamine at the cutoff of 1000 ng/mL dmethamphetamine in human urine to assist in screening of drugs of abuse samples. For In vitro Diagnostic Use.
-
- Substantial Equivalence: Status Stik™ THC/OPI/COC/MET is substantially equivalent to the K990786, Status DS" DOA 10 for THC, COC, MET and K981771, Status DS" OPI for OPI. All three products use the same assay principle and are immunochromatographic assays to detect THC, opiates, cocaine and methamphetamine qualitatively. The detecting cutoff levels are the same. The tests demonstrated 100 % correlation when more than 90 specimens for each drug were compared respectively. The difference is Status Stik™
1
THC/OPI/COC/MET detects four drugs, while Status DS™ DOA 10 detects seven, other 111c/of resolver in addition to THC, cocaine and methamphetamine, and Status DS™ OPI detects morphine only.
- Conclusion: The device is substantially equivalent to the legally marketed devices K990786, -110 at 110 11 - 10 abbankary operature - 11 - 11 - 11 - 11 - 11 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10
2
510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR Part 807.92.
The assigned 510(k) number is:
- Date of Summary: Dec.12, 2001
- Princeton BioMeditech Corperation 2. Submitted by: 4242 U.S. Route 1, Monmouth Jct., NJ 08852 PHONE 732-274-1000 732-274-1010 FAX Contact Person: Jemo Kang, Ph.D., Director
-
- Device Name
Trade Names: LifeSign® Home Drug Test (THC/OPI/COC/MET) Common or Usual Name: Immunoassay for detection of THC, opiates, cocaine, and methamphetamine in urine Classification Name: Drugs of Abuse Analysis Systems, Toxicology (91DKE, 91DJG, 91DIO for Enzyme Immunoassay, 91LAG for HPLC)
-
- Device Description: LifeSign® Home Drug Test (THC/OPVCOC/MET) is simple one step immunochromatographic test for the rapid, qualitative, simultaneous detection of THC, opiates, cocaine, and methamphetamine.
-
- Intended Use: LifeSign® Home Drug Test is designed for the qualitative detection of THC at the cutoff of 50 ng/mL 11-nor-A2-THC-9-carboxylic acid, opiates at the cutoff of 2000 ng/mL morphine, cocaine at the cutoff of 300 ng/mL benzoylecgonine, and methamphetamine at the cutoff of 1000 ng/mL d-methamphetamine in human urine to assist in screening of drugs of abuse samples. For In vitro Diagnostic Use. This test is intended for use in the home to assist in preventing drug abuse.
-
- Substantial Equivalence: LifeSign® Home Drug Test is substantially equivalent to the K990786, Status DS™ DOA 10 for THC, COC, MET and K981771, Status DS™ OPI for OPI. All three products use the same assay principle and are immunochromatographic assays to detect THC, opiates, cocaine and methamphetamine qualitatively. The detecting cutoff levels are the same. The tests demonstrated 100 % correlation when more than 90 specimens for each drug were compared respectively. The difference is that LifeSign® Home Drug Test detects four drugs, while Status DS™ DOA 10 detects seven other drugs of abuse in addition to THC, cocaine and methamphetamine, and Status DS™ OPI detects morphine only.
3
- Consumer Study: In a consumer study, LifeSign® Home Drug Test (THC/OPI/ COC/ MET) showed over 95% overall accuracy.
Conclusion: The device is substantially equivalent to the legally marketed devices K990786, Status DS™ DOA 10 (MET/OPI/COC/THC/PCP/BZO/BAR/ MTD/TCA/AMP) and K981771, Status DS™ OPI. The product is safe in the hands of the lay user.
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized image of three abstract shapes that resemble birds in flight, stacked on top of each other.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Jemo Kang, Ph.D. Director . Princeton BioMeditech Corporation 4242 U.S. Route 1 Monmouth Junction, NJ 08852-1905
Re: K014193
Trade/Device Names: LifeSign®Home Drug Test (THC/OPI/COC/MET) Status Stik™ THC/OPI/COC/MET, AccuSign®Stik THC/OPI/COC/MET, AccuStik"1d DOA4.AccuSign® DOA4, Status DSTM DOA4, AccuStrip™ DOA4 Regulation Numbers: 21 CFR 862.3610; 21 CFR 862.3870; 21 CFR 862.3250; 21 CFR 862.3650 Regulation Names: Methamphetamine test system; Cannabinoid test system; Cocaine and cocaine metabolite test system: Opiate test system Regulatory Class: Class II Product Codes: MVO; DJC; LDJ; DIO; DIO; DJG Dated: April 9, 2002 Received: April 10, 2002
Dear Dr. Kang:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
5
Page 2
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must or mry with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) rms letter notification. The FDA finding of substantial equivalence of your device to a legally premaince nedicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
ely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
6
| Page | |
|---|---|
| ------ | -- |
510(k) Number (if known):
Device Name: Status Stik™ THC/OPI/COC/MET, AccuSign® Stik THC/OPI/COC/MET, IC. Status Dilk - Tric. AccuSign® DOA4, Status DS™ DOA4, AccuStrip™ DOA4
Indications For Use:
Immunoassay for the qualitative detection of THC metabolite, opiates, cocaine metabolite, methamphetamine in urine to assist in screening of drugs of abuse. For in vitro Diagnostic Use
The detection cutoff concentrations are as follows:
| THC | 11-nor-Δ9-THC-9-carboxylic acid | 50 ng/ml |
|---|---|---|
| OPI | Morphine | 2000 ng/ml |
| COC | Benzoylecgonine | 300 ng/ml |
| MET | D-Methamphetamine | 1000 ng/ml |
Trade Names for each device format
| Stick: | Status Stik TM THC/OPI/COC/MET, AccuSign ® Stik THC/OPI/COC/MET, AccuStik TM DOA4 |
|---|---|
| Card: | AccuSign ® DOA4, Status DS TM DOA4 |
| Strip: | AccuStrip TM DOA4 |
| Division Sign-Off | |
|---|---|
| Division of Clinical Laboratory Device | |
| 510(k) Number | K014193 |
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)# Concurrence of CDRH Office of Device Evaluation (ODE)
Professional Use: Prescription Use: X (Per 21 CFR 801.109)
OR
Over The Counter Use: __
(Optional Format 1-2-96)
7
2014193 510(k) Number (if known):
Device Name: LifeSign® Home Drug Test (THC/OPI/COC/MET)
Indications For Use:
Immunoassay for the qualitative detection of THC metabolite, opiates, cocaine metabolite, methamphetamine in urine to assist in screening of drugs of abuse samples at home or The detection cutoff concentrations are as work places. For in vitro Diagnostic Use. follows:
| THC | 11-nor-Δ⁹-THC-9-carboxylic acid | 50 ng/ml |
|---|---|---|
| OPI | Morphine | 2000 ng/ml |
| COC | Benzoylecgonine | 300 ng/ml |
| MET | D-Methamphetamine | 1000 ng/ml |
Liam Cooper
Division Sign-Off) Ilnical Laboratory Cavices Division o 510(k) Number
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH Office of Device Evaluation (ODE)
Professional Use:_
Prescription Use: (Per 21 CFR 801.109) OR
Over The Counter Use: _X
(Optional Format 1-2-96)